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Our laboratory has evaluated therapeutic strategies for
pulmonary fibrosis in rodents, humans and recently non-
human primates. Clinically, our studies have evaluated
biomarkers of susceptibility to fibrosis that may lead to
new innovations on treatment strategies, prevention, and
biomarkers. It is anticipated that these biomarkers may
also be applied in animal models of disease. Modeling
idiopathic pulmonary fibrosis in animals is complicated by
the complexity of the disease, and often limited by limita-
tions in the model. Bleomycin induced fibrosis has been
extensively characterized and is the workhorse of the phar-
macology community. The utility of this model is limited
by its ability to resolve and its relatively artificial mode of
action (although there are many commonalities that have
been confirmed in humans). We have evaluated permuta-
tions of the model to optimize the homogeneity and
stability of the lung injury from Bleomycin treatment,
including delivering it by inhalation in both rodents and
recently non-human primates (NHP). The model can be
utilized in a number of ways to evaluate therapeutic inter-
vention. A limitation is that many compounds which have
been successful at mitigating bleomycin induced injury in
the model have not been successful at mitigating human
fibrosis. As a result, we have enhanced our models to per-
mit a two stage evaluation that uses radiation induced pul-
monary fibrosis subsequent to bleomycin. Mice are
irradiated once and develop fibrosis between 16-24 weeks
afterwards. The advantage of this approach is that the
mechanism of fibrotic progression has some complements
to bleomycin but also some important contrasts. A disad-
vantage is the time frame of the model, which makes it of
limited utility for relatively rapid screening of molecules.
The important lesson learned from our combined preclini-
cal and clinical model evaluations is that it is important to
continue to utilize clinical and translational techniques
(including in vitro) to determine the mode of action in
addition to the pharmacology. Because of the large num-
ber of false positives that have been observed in the bleo-
mycin fibrosis model, it is important to complement it
with alternative approaches such as radiation and exami-
nation in multiple species (e.g., NHP). Further, the noncli-
nical data must offer informative mechanistic information
both to enhance the biomarkers available in the clinic and
to ensure that the mode of action is feasible in humans.
We will present information on several of these models,
utilizing case studies of several recent published therapeu-
tics and therapeutic pathways.
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